Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments

Completed · Phase 2

Conditions studied: Colorectal Neoplasm

In brief

This study will test if there is any survival benefit in patients with refractory metastatic colorectal cancer that receive CP-751, 871.

Key facts

Study ID: NCT00560560
Run by: Pfizer
People needed: 168
Starts: 2007-12-01
Expected to finish: 2010-09-01
Last updated by the study team: 2013-05-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients who have stage IV colorectal cancer
Patients whose disease has worsened despite prior anti-cancer therapy
Patients who have satisfactory bonemarrow, kidney and liver function

You may not qualify if…

Patients who are being simultaneously treated with another anti-cancer therapy.
Patients who have previously received anti-cancer therapy that works like CP-751, 871 (targets insulin-like growth factor receptor)
Patients that are pregnant or breast-feeding

Where it is running

Pfizer Investigational Site — San Francisco, California, United States
Pfizer Investigational Site — Dallas, Texas, United States
Pfizer Investigational Site — Elche, Alicante, Spain
Pfizer Investigational Site — Barcelona, Barcelona, Spain
Pfizer Investigational Site — L'Hospitalet de Llobregat, Barcelona, Spain
Pfizer Investigational Site — Seville, Sevilla, Spain
Pfizer Investigational Site — Peterborough, Cambridgeshire, United Kingdom
Pfizer Investigational Site — Leicester, Leicestershire, United Kingdom
Pfizer Investigational Site — Cardiff, United Kingdom
Pfizer Investigational Site — Glasgow, United Kingdom
Pfizer Investigational Site — Peterborough, United Kingdom
Pfizer Investigational Site — Southampton, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.